India’s 1st medical technology institute at AMTZ gets 100% govt financial support

The Kalam Institute of Health Technology (KIHT), India’s first institute dedicated to medical technology located at Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam, has received official approval for 100 per cent financial support from the Department of Bio-technology, Government of India.


KIHT approval comes after the launch of ‘National Biopharma Mission’ “ an industry-academia collaboration for accelerating discovery research to early development for biopharmaceuticals.

The National Biopharma Mission includes an investment of $125 million from the Government of India and an equal contribution as a loan from the World Bank. It is anticipated to be a game changer for the Indian biopharmaceutical and medical devices industry.

Named after India’s 11th President Dr APJ Abdul Kalam, KIHT has been set up with the aim to identify critical gaps in medical technology and suggest the government to do focused spending on such areas and help bridge the gap between academic research and industrial market access, by auctioning of patents and prototypes available with government funded academic research institutions.


KIHT will broadly focus on innovation and market access, enabling technology transfer and support for research and development.

Located within AMTZ campus, India’s first state-of-the-art medical devices manufacturing park, KIHT will have direct access to academia and industry. Launch of KIHT is scheduled to be done soon by Andhra Pradesh Chief Minister N. Chandra Babu Naidu.

AMTZ is one of the fastest growing Government of India-supported projects in Andhra Pradesh. Construction activity at the 270-acre iconic park dedicated to medical device manufacturing was initiated earlier this month. AMTZ has recently received the ‘Most Innovative MedTech Zone’ award.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top